Management of angiosarcoma.
Identifieur interne : 004467 ( PubMed/Curation ); précédent : 004466; suivant : 004468Management of angiosarcoma.
Auteurs : G Thomas Budd [États-Unis]Source :
- Current oncology reports [ 1523-3790 ] ; 2002.
Descripteurs français
- KwdFr :
- Facteurs de l'âge, Facteurs sexuels, Femelle, Humains, Hémangiosarcome (), Hémangiosarcome (anatomopathologie), Hémangiosarcome (étiologie), Inhibiteurs de l'angiogenèse (usage thérapeutique), Interférons (usage thérapeutique), Lymphoedème (anatomopathologie), Mâle, Pronostic, Récidive tumorale locale, Résultat thérapeutique, Tumeurs cutanées (), Tumeurs de la tête et du cou (), Tumeurs de la tête et du cou (anatomopathologie), Tumeurs de la tête et du cou (étiologie), Tumeurs du foie (), Tumeurs du foie (étiologie).
- MESH :
- anatomopathologie : Hémangiosarcome, Lymphoedème, Tumeurs de la tête et du cou.
- usage thérapeutique : Inhibiteurs de l'angiogenèse, Interférons.
- étiologie : Hémangiosarcome, Tumeurs de la tête et du cou, Tumeurs du foie.
- Facteurs de l'âge, Facteurs sexuels, Femelle, Humains, Hémangiosarcome, Mâle, Pronostic, Récidive tumorale locale, Résultat thérapeutique, Tumeurs cutanées, Tumeurs de la tête et du cou, Tumeurs du foie.
English descriptors
- KwdEn :
- Age Factors, Angiogenesis Inhibitors (therapeutic use), Female, Head and Neck Neoplasms (etiology), Head and Neck Neoplasms (pathology), Head and Neck Neoplasms (therapy), Hemangiosarcoma (etiology), Hemangiosarcoma (pathology), Hemangiosarcoma (therapy), Humans, Interferons (therapeutic use), Liver Neoplasms (etiology), Liver Neoplasms (therapy), Lymphedema (pathology), Male, Neoplasm Recurrence, Local, Prognosis, Sex Factors, Skin Neoplasms (therapy), Treatment Outcome.
- MESH :
- chemical , therapeutic use : Angiogenesis Inhibitors, Interferons.
- etiology : Head and Neck Neoplasms, Hemangiosarcoma, Liver Neoplasms.
- pathology : Head and Neck Neoplasms, Hemangiosarcoma, Lymphedema.
- therapy : Head and Neck Neoplasms, Hemangiosarcoma, Liver Neoplasms, Skin Neoplasms.
- Age Factors, Female, Humans, Male, Neoplasm Recurrence, Local, Prognosis, Sex Factors, Treatment Outcome.
Abstract
Angiosarcoma is an uncommon tumor that presents in several scenarios. Although angiosarcoma can occur in any organ, it typically presents in the following settings: 1) in the face or scalp among elderly patients, 2) with chronic lymphedema, 3) after radiotherapy, or 4) as a hepatic primary. In all of these situations, angiosarcoma is associated with multifocality and an insidious growth pattern, making local control difficult. Doxorubicin-ifosfamide chemotherapy produces a modest response rate, and paclitaxel appears to be useful for scalp and facial angiosarcomas. However, improvement in systemic therapy is clearly needed. One logical strategy is to investigate antiangiogenic therapies in this endothelial tumor. Improved therapy for this tumor will come only with greater understanding of its biology.
PubMed: 12354365
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004467
Links to Exploration step
pubmed:12354365Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Management of angiosarcoma.</title><author><name sortKey="Budd, G Thomas" sort="Budd, G Thomas" uniqKey="Budd G" first="G Thomas" last="Budd">G Thomas Budd</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA. buddg@ccf.org</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, Cleveland, OH 44195</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:12354365</idno><idno type="pmid">12354365</idno><idno type="wicri:Area/PubMed/Corpus">004467</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004467</idno><idno type="wicri:Area/PubMed/Curation">004467</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004467</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Management of angiosarcoma.</title><author><name sortKey="Budd, G Thomas" sort="Budd, G Thomas" uniqKey="Budd G" first="G Thomas" last="Budd">G Thomas Budd</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA. buddg@ccf.org</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, Cleveland, OH 44195</wicri:regionArea></affiliation></author></analytic><series><title level="j">Current oncology reports</title><idno type="ISSN">1523-3790</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term><term>Angiogenesis Inhibitors (therapeutic use)</term><term>Female</term><term>Head and Neck Neoplasms (etiology)</term><term>Head and Neck Neoplasms (pathology)</term><term>Head and Neck Neoplasms (therapy)</term><term>Hemangiosarcoma (etiology)</term><term>Hemangiosarcoma (pathology)</term><term>Hemangiosarcoma (therapy)</term><term>Humans</term><term>Interferons (therapeutic use)</term><term>Liver Neoplasms (etiology)</term><term>Liver Neoplasms (therapy)</term><term>Lymphedema (pathology)</term><term>Male</term><term>Neoplasm Recurrence, Local</term><term>Prognosis</term><term>Sex Factors</term><term>Skin Neoplasms (therapy)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Facteurs de l'âge</term><term>Facteurs sexuels</term><term>Femelle</term><term>Humains</term><term>Hémangiosarcome ()</term><term>Hémangiosarcome (anatomopathologie)</term><term>Hémangiosarcome (étiologie)</term><term>Inhibiteurs de l'angiogenèse (usage thérapeutique)</term><term>Interférons (usage thérapeutique)</term><term>Lymphoedème (anatomopathologie)</term><term>Mâle</term><term>Pronostic</term><term>Récidive tumorale locale</term><term>Résultat thérapeutique</term><term>Tumeurs cutanées ()</term><term>Tumeurs de la tête et du cou ()</term><term>Tumeurs de la tête et du cou (anatomopathologie)</term><term>Tumeurs de la tête et du cou (étiologie)</term><term>Tumeurs du foie ()</term><term>Tumeurs du foie (étiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Interferons</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Hémangiosarcome</term><term>Lymphoedème</term><term>Tumeurs de la tête et du cou</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Head and Neck Neoplasms</term><term>Hemangiosarcoma</term><term>Liver Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Head and Neck Neoplasms</term><term>Hemangiosarcoma</term><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Head and Neck Neoplasms</term><term>Hemangiosarcoma</term><term>Liver Neoplasms</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Inhibiteurs de l'angiogenèse</term><term>Interférons</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Hémangiosarcome</term><term>Tumeurs de la tête et du cou</term><term>Tumeurs du foie</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>Female</term><term>Humans</term><term>Male</term><term>Neoplasm Recurrence, Local</term><term>Prognosis</term><term>Sex Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Facteurs de l'âge</term><term>Facteurs sexuels</term><term>Femelle</term><term>Humains</term><term>Hémangiosarcome</term><term>Mâle</term><term>Pronostic</term><term>Récidive tumorale locale</term><term>Résultat thérapeutique</term><term>Tumeurs cutanées</term><term>Tumeurs de la tête et du cou</term><term>Tumeurs du foie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Angiosarcoma is an uncommon tumor that presents in several scenarios. Although angiosarcoma can occur in any organ, it typically presents in the following settings: 1) in the face or scalp among elderly patients, 2) with chronic lymphedema, 3) after radiotherapy, or 4) as a hepatic primary. In all of these situations, angiosarcoma is associated with multifocality and an insidious growth pattern, making local control difficult. Doxorubicin-ifosfamide chemotherapy produces a modest response rate, and paclitaxel appears to be useful for scalp and facial angiosarcomas. However, improvement in systemic therapy is clearly needed. One logical strategy is to investigate antiangiogenic therapies in this endothelial tumor. Improved therapy for this tumor will come only with greater understanding of its biology.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12354365</PMID><DateCreated><Year>2002</Year><Month>09</Month><Day>30</Day></DateCreated><DateCompleted><Year>2003</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2005</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1523-3790</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>6</Issue><PubDate><Year>2002</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Current oncology reports</Title><ISOAbbreviation>Curr Oncol Rep</ISOAbbreviation></Journal><ArticleTitle>Management of angiosarcoma.</ArticleTitle><Pagination><MedlinePgn>515-9</MedlinePgn></Pagination><Abstract><AbstractText>Angiosarcoma is an uncommon tumor that presents in several scenarios. Although angiosarcoma can occur in any organ, it typically presents in the following settings: 1) in the face or scalp among elderly patients, 2) with chronic lymphedema, 3) after radiotherapy, or 4) as a hepatic primary. In all of these situations, angiosarcoma is associated with multifocality and an insidious growth pattern, making local control difficult. Doxorubicin-ifosfamide chemotherapy produces a modest response rate, and paclitaxel appears to be useful for scalp and facial angiosarcomas. However, improvement in systemic therapy is clearly needed. One logical strategy is to investigate antiangiogenic therapies in this endothelial tumor. Improved therapy for this tumor will come only with greater understanding of its biology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Budd</LastName><ForeName>G Thomas</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA. buddg@ccf.org</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Oncol Rep</MedlineTA><NlmUniqueID>100888967</NlmUniqueID><ISSNLinking>1523-3790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="N">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006394" MajorTopicYN="N">Hemangiosarcoma</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>49</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>10</Month><Day>2</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>3</Month><Day>12</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>10</Month><Day>2</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12354365</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004467 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 004467 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:12354365
|texte= Management of angiosarcoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:12354365" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |